We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > progeroid laminopathies

News List

FDA Approves Zokinvy for Hutchinson-Gilford Progeria Syndrome americanpharmaceuticalreview
December 08, 2020
Eiger BioPharmaceuticals announced the U.S. Food and Drug Administration (FDA) has approved ZokinvyTM (lonafarnib) for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient Progeroid Laminopathies (PL).
FDA approves first treatment for rare paediatric genetic diseases europeanpharmaceuticalreview
November 26, 2020
Zokinvy (lonafarnib) capsules have been approved for the treatment of Hutchinson-Gilford progeria syndrome and certain progeroid laminopathies in patients over one year old.